非肌层浸润性膀胱癌的灌注化学疗法研究进展

Research Progress in Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer

膀胱癌是常见的泌尿系统恶性肿瘤,其中75%以上被诊断为非肌层浸润性膀胱癌(NMIBC)。经尿道膀胱肿瘤电切术(TURBT)是NMIBC标准诊疗手段,但由于NMIBC易复发的特点,通常根据肿瘤分期、分级情况辅以适宜的膀胱灌注疗法可以降低肿瘤复发率。本文就灌注化疗药物、药物传递系统以及临床治疗策略的现状和进展进行综述,以期对临床NMIBC灌注化疗的应用提供参考。

Bladder cancer is the most common malignant solid tumor in urinary system. More than 75% cases of bladder cancer have been diagnosed as non-muscle-invasive bladder cancer （NMIBC）. Transurethral resection of bladder tumor （TURBT） is the standard method for the diagnosis and treatment for bladder cancer, however, due to its problem of recurrence, adjuvant intravesieal therapy with either immunotherapy or chemotherapy has been used to reduce recurrence and achieve better efficacy for the patients in appropriate stages. The review focused on current progress in chemotherapy agents, targeted bladder drug delivery systems and treatment strategies for NMIBC, which would provide guidance for clinical intravesical chemotherapy.